The EPS miss and slowing U.S. revenue growth (unit growth of 13% but revenue only +3% due to mix) are concerning. Watch for Q2 revenue guidance of $20M — if achieved, it would imply ~5% YoY growth, still below the full-year 8% target. Monitor cash burn trajectory; at current rate, cash runway is ~3 quarters without additional financing.
Price Chart
Executive Summary
TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M consensus, and an EPS of -$0.21 (GAAP), which is worse than the -$0.19 consensus estimate. The company reiterated full-year 2026 revenue guidance of at least 8% growth, but Q1 growth was only 3%, and net loss widened to $12.3M from $11.3M a year ago. The stock may face pressure from the EPS miss and decelerating revenue growth, partially offset by the reiterated guidance and European momentum.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $19.1M, +3% YoY (vs consensus $19.0M)
- GAAP EPS of -$0.21 vs consensus -$0.19 (miss of 10.5%)
- Net loss widened to $12.3M from $11.3M in Q1 2025
- Gross margin declined to 65.7% from 67.6% due to higher excess inventory charges
- Reiterated full-year 2026 revenue guidance of at least 8% growth
- Q2 2026 revenue guided to ~$20.0M
- Cash and equivalents of $39.5M, down from $50.8M at year-end 2025
- European revenue grew 41% YoY; U.S. revenue growth was modest due to product mix headwinds
Financial Impact
Revenue beat consensus by ~$0.1M (0.5%), but EPS missed by $0.02 (10.5%). Net loss increased $1.0M YoY.
Risk Factors
- Cash burn: $11.3M in Q1, leaving ~3.5 quarters of runway at current pace
- U.S. product mix headwinds pressuring revenue growth despite unit growth
- GAAP EPS miss of 10.5% vs consensus may disappoint investors
- Full-year 8% growth guidance requires acceleration from Q1's 3%
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293358 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $0.7380 $1.24 | ▲ +68.02% | ▲ +68.21% | $1.19 (+61.25%) |
Aug 10, 2026 7w ago | 8-K | $0.7900 $0.9113 | ▼ −15.35% | ▼ −16.41% | $1.19 (−50.63%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
May 12, 2026 20w ago | 8-K | $0.9600 $0.9120 | ▼ −5.00% | ▼ −4.39% | $1.19 (+23.96%) |
May 12, 2026 20w ago | Press Release | $0.9600 $0.9120 | ▲ +5.00% | ▲ +4.39% | $1.19 (−23.96%) |
Apr 30, 2026 22w ago | 8-K | $0.9890 $0.9000 | ▼ −9.00% | ▼ −14.28% | $1.19 (+20.32%) |
Apr 21, 2026 23w ago | Press Release | $0.6250 $0.8600 | ▲ +37.60% | ▲ +34.43% | $1.19 (+90.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access